Stocktoria
Senti Biosciences Holdings, Inc. SNTI
Senti Biosciences Holdings, Inc. (SNTI) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $22,000 at a -279263.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SNTI | Senti Biosciences Holdings, Inc. | 2/9 | — | — | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | 4/9 | -1.04 | — | — |
| ENTX | Entera Bio Ltd. | 2/9 | — | — | — |
| SRRK | Scholar Rock Holding Corp | 1/9 | -9.91 | — | -100% |
| SABS | SAB Biotherapeutics, Inc. | 3/9 | 6.9 | 21.9 | — |
| RVMD | Revolution Medicines, Inc. | 1/9 | -0.01 | — | — |
| PMCB | PharmaCyte Biotech, Inc. | 4/9 | 13.39 | — | — |
About Senti Biosciences Holdings, Inc.
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
FAQ
Is SNTI financially healthy?
Senti Biosciences Holdings, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does SNTI pay a dividend?
No, Senti Biosciences Holdings, Inc. does not currently pay a dividend.
How profitable is SNTI?
In FY2025, Senti Biosciences Holdings, Inc. had a net margin of -279263.6% and a return on equity of -1099.3%.
What is the analyst price target for SNTI?
The average Wall-Street price target for Senti Biosciences Holdings, Inc. is $13.00, about 3364.8% above the recent price, from 3 analysts (consensus: strong buy).
Is SNTI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Senti Biosciences Holdings, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.